Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Accretion PharmaceuticalsNSE:ACCPL +2.36%21 EV-to-EBIT is 16.16 as of Aug. 17, 2026, which is 136% above its 10-year median of 6.85. GuruFocus rates NSE:ACCPL with a GF Score™ of 21/100. The stock has 6 warning signs investors should review. Among 683 Drug Manufacturers companies, Accretion Pharmaceuticals ranks better than 50.22% on this metric.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Accretion Pharmaceuticals's Enterprise Value for the quarter that ended in Mar. 2026 was ₹789.4 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Accretion Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ₹139.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accretion Pharmaceuticals EV-to-EBIT Related Terms
Accretion Pharmaceuticals EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:ACCPL vs LLY, JNJ, ABBV: EV-to-EBIT Comparison
For the Drug Manufacturers - General subindustry, Accretion Pharmaceuticals's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Accretion Pharmaceuticals EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Accretion Pharmaceuticals's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Accretion Pharmaceuticals's EV-to-EBIT falls into.
Accretion Pharmaceuticals's current Enterprise Value is ₹2,250.6 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Accretion Pharmaceuticals's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was ₹139.3 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Accretion Pharmaceuticals (NSE:ACCPL) has a EV-to-EBIT of 16.16 as of Aug. 17, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Accretion Pharmaceuticals and its competitors. This is 136% above median its historical median of 6.85. Over the past decade, Accretion Pharmaceuticals' EV-to-EBIT has ranged from 5.42 to 16.16. According to the industry distribution chart, Accretion Pharmaceuticals ranks #340 out of 683 companies in the Drug Manufacturers industry, placing it in the top 49.8%.
Is Accretion Pharmaceuticals' EV-to-EBIT too high?
Accretion Pharmaceuticals' current EV-to-EBIT of 16.16 is 136% above median its 10-year median of 6.85. Over the past 10 years, this metric has ranged from a low of 5.42 to a high of 16.16. The Drug Manufacturers industry median EV-to-EBIT is 15.94. Accretion Pharmaceuticals' value of 16.16 is 1.4% above this industry median. Based on the distribution chart, Accretion Pharmaceuticals ranks #340 out of 683 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Accretion Pharmaceuticals has a GF Score™ of 21/100, reflecting its overall financial health beyond just this single metric.
How does Accretion Pharmaceuticals' EV-to-EBIT compare to LLY and JNJ?
According to the Drug Manufacturers industry distribution chart, Accretion Pharmaceuticals ranks #340 out of 683 companies for EV-to-EBIT. This puts Accretion Pharmaceuticals in the upper half of its industry. The industry median EV-to-EBIT is 15.94. Accretion Pharmaceuticals' value of 16.16 is 1.4% above this benchmark. Historically, Accretion Pharmaceuticals' own EV-to-EBIT has ranged from 5.42 to 16.16 over the past decade. While the company's 10-year median is 6.85 vs. the industry median of 15.94, Accretion Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.94, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Accretion Pharmaceuticals's current EV-to-EBIT of 16.16 is 1.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Accretion Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accretion Pharmaceuticals's current EV-to-EBIT is 16.16, which is 136% above median its own 10-year median of 6.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accretion Pharmaceuticals stock overvalued right now?
Accretion Pharmaceuticals (NSE:ACCPL) has a current EV-to-EBIT of 16.16. The current EV-to-EBIT is 16.16, which is 136% above median its 10-year median of 6.85 and 1.4% above the Drug Manufacturers industry median of 15.94. Accretion Pharmaceuticals' overall GF Score™ is 21/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Accretion Pharmaceuticals (NSE:ACCPL), the current EV-to-EBIT is 16.16 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Accretion Pharmaceuticals Ltd is engaged in the manufacturing of Medicinal & Pharmaceutical Products. The company manufactures tablets, oral liquid, capsule, cream, ointment, mouthwash, dusting powder, gel, ear drops, lotion, shampoo, powder, syrup, among others.
21GF Score
Get the complete analysis for NSE:ACCPL
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:ACCPL has been successfully added to your 
